期刊
ADVANCED DRUG DELIVERY REVIEWS
卷 173, 期 -, 页码 331-348出版社
ELSEVIER
DOI: 10.1016/j.addr.2021.04.002
关键词
Transdermal; Microneedles; HIV; Contraception; Women's health; Long-acting
资金
- United States Agency for International Development (USAID) through the United States President's Emergency Plan for AIDS Relief (PEPFAR) [AID-OAA-A-17-00015]
Microarray patches (MAPs) are a novel platform for delivering hormonal contraception and antiretroviral drugs, providing enhanced drug delivery to the systemic circulation. These minimally invasive patches can be self-administered by users, reducing the burden on healthcare personnel and eliminating the risk of needle-stick injuries.
Despite the existence of a variety of contraceptive products for women, as well as decades of research into the prevention and treatment of human immunodeficiency virus (HIV), there is still a globally unmet need for easily accessible, acceptable, and affordable products to protect women's sexual and reproductive health. Microarray patches (MAPs) are a novel platform being developed for the delivery of hormonal contraception and antiretroviral drugs. MAPs provide enhanced drug delivery to the systemic circulation via the transdermal route when compared to transdermal patches, oral and injectable formulations. These minimally invasive patches can be self-administered by the user, reducing the burden on health care personnel. Since MAPs represent needle-free drug delivery, no sharps waste is generated after application, thereby eliminating possible MAP reuse and risk of needle-stick injuries. This review discusses the administration of contraceptive and antiretroviral drugs using MAPs, their acceptability by end-users, and the future perspective of the field. (C) 2021 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据